Inaticabtagene autoleucel
纳基奥仑赛CD19 CAR-T therapy retained in the 2026 Commercial List (#13) with an expanded indication scope adding adult relapsed/refractory LBCL alongside r/r B-ALL.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字S20230065
- Initial Approval Date
- Nov 7, 2023
- Notice Published
- Nov 8, 2023
- MAH
- Juventas Cell Therapy Ltd. (合源生物科技股份有限公司)
- Approved Scope
- Conditional approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL); later expanded to adult r/r large B-cell lymphoma (r/r LBCL).
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
Announced · Effective Jan 1, 2027- 2026 List Entry
- #13 · 源瑞达
- Validity Period
- 2026-01-01 to 2027-12-31
- MAH / Authorized Entity
- Juventas Cell Therapy Ltd.
- Listed Indication Scope
- Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.
Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字S20230065 | Injection (CAR-T) (注射液) | Initial Approval Conditional approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL); later expanded to adult r/r large B-cell lymphoma (r/r LBCL). 附条件批准用于治疗成人复发或难治性B细胞急性淋巴细胞白血病(r/r B-ALL);后续扩展至成人复发或难治性大B细胞淋巴瘤(r/r LBCL)。 | Approved: 2023-11-07 Published: 2023-11-08 | Juventas Cell Therapy Ltd. |
Change Timeline
- (2027-01-01)Commercial List· Catalog published: Nov 14, 2026
2026 Commercial List · Indication Expanded (#13)
Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.
Chinese original: 本品适用于成人复发或难治性B细胞急性淋巴细胞白血病。本品适用于经过二线或以上系统性治疗后成人复发或难治性大B细胞淋巴瘤,包括:弥漫大B细胞淋巴瘤非特指型、滤泡性淋巴瘤转化的大B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤。
NHSA · PDF p.3Verified 2026-11-20 - (2026-01-01)Commercial List· Catalog published: Dec 7, 2025
2025 Commercial List · Listed (#11)
Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Chinese original: 适用于成人复发或难治性B细胞急性淋巴细胞白血病。
NHSA · PDF p.3Verified 2026-11-20 - (2023-11-07)NMPA Approval· Notice published: Nov 8, 2023
NMPA Initial Marketing Approval (国药准字S20230065)
Conditional approval for adult relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL); later expanded to adult r/r large B-cell lymphoma (r/r LBCL).
Chinese original: 附条件批准用于治疗成人复发或难治性B细胞急性淋巴细胞白血病(r/r B-ALL);后续扩展至成人复发或难治性大B细胞淋巴瘤(r/r LBCL)。
NMPA · NMPA Registration S20230065Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14商业健康保险创新药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07商业健康保险创新药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20